Riskpilot← Back to searchSign inGet full accessSvampen Apotek AB
ABActiveOrg 5591903025Mejeritorget 8 BRetail sale of pharmaceutical products · NACE 4773Est. 20190 employees
Revenue 2024
SEK 0
EBITDA margin
—
-731% vs 2023
Equity ratio
47.8%
Financial strength
Net profit 2024
SEK 280K
+39% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -17K | -731% |
| Net profit | SEK 280K | +39% |
| Total assets | SEK 693K | +68% |
| Equity | SEK 331K | +37% |
| Employees | 0 | — |
Legal name
Svampen Apotek AB
Org number
5591903025
Legal form
Aktiebolag
NACE code
4773 · Retail sale of pharmaceutical products
Founded
9 januari 2019
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Äga och förvalta aktier i ett annat bolag. Vi kommer att driva ett apotek i Örebro.
Address
Mejeritorget 8 B
Email
orebro.svampen@apoteksgruppen.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −6 | −1 | −1 | 3 | −17 |
| Depreciation & amort. | −0 | −0 | — | — | −0 |
| EBIT | −6 | −1 | −1 | 3 | −17 |
| Net financials | — | — | — | 198 | 297 |
| Profit before tax | −6 | −1 | −1 | 201 | 280 |
| Tax | −0 | −0 | — | — | −0 |
| Net profit | −6 | −1 | −1 | 201 | 280 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 843 | 1 125 | 801 | 413 | 693 |
| Equity | 43 | 42 | 41 | 241 | 331 |
| Long-term debt | 0 | 0 | — | — | 0 |
| Short-term debt | 800 | 1 084 | 760 | 172 | 362 |
| Total debt | 800 | 1 084 | 760 | 172 | 362 |
EBITDA margin
-1700000.0%
This company
15.8%
Market median
-10759594% vs market
20202024
Equity ratio
47.8%
This company
38.2%
Market median
+25% vs market
20202024
Return on equity
84.6%
This company
18.4%
Market median
+360% vs market
20202024
Net profit margin
28000000.0%
This company
8.1%
Market median
+345678912% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
1.09×
This company
0.62×
Market median
-76% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (4) | ||
| Deputy Board Member | 2022 | |
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
| Board of Directors | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Svampen Apotek AB 
Apoteksgruppen i Örebro Nr 4 ABBoard members of Svampen Apotek AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Evoun Kebrail | Deputy Board Member | 0 companies |
| Mouna Lahdo Nederfeldt | Chairman | 0 companies |
| Lars Kåre Andreas Apelqvist | Deputy Board Member | 0 companies |
| Lars Kåre Allan Apelqvist | Board of Directors | 0 companies |